USD 1.01
(0.0%)
Year | Eps | Eps Growth |
---|---|---|
2024 | - USD | 100.0% |
2023 | -0.01 USD | 82.7% |
2022 | -0.07 USD | 75.48% |
2021 | -0.29 USD | -229.17% |
2020 | -0.09 USD | -313.62% |
2019 | -0.02 USD | 0.0% |
2018 | -0.02 USD | 0.0% |
2014 | -22.77 USD | -11384900.0% |
2013 | -0.00 USD | 99.83% |
2012 | -0.12 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.00 USD | 30.77% |
2024 Q3 | -0.00 USD | -33.33% |
2024 Q4 | -0.01 USD | -516.67% |
2024 Q1 | -0.00 USD | 0.0% |
2024 FY | - USD | 13.01% |
2023 Q1 | -0.01 USD | 100.0% |
2023 Q2 | -0.00 USD | 96.33% |
2023 Q4 | - USD | 100.0% |
2023 FY | - USD | 82.7% |
2023 Q3 | -0.00 USD | -175.0% |
2022 Q4 | -4753.09 USD | -108024872.73% |
2022 FY | - USD | 75.48% |
2022 Q3 | 0.00 USD | 122.0% |
2022 Q2 | -0.02 USD | 59.92% |
2022 Q1 | -0.05 USD | 39.59% |
2021 FY | - USD | -229.17% |
2021 Q4 | -0.08 USD | -3.25% |
2021 Q3 | -0.08 USD | -3.9% |
2021 Q1 | -0.04 USD | -139.52% |
2021 Q2 | -0.08 USD | -92.5% |
2020 Q2 | -0.05 USD | 62.08% |
2020 FY | - USD | -313.62% |
2020 Q4 | -0.02 USD | 31.56% |
2020 Q3 | -0.02 USD | 50.51% |
2020 Q1 | -0.13 USD | 0.0% |
2019 FY | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2015 Q2 | -12.43 USD | 69.24% |
2015 Q1 | -40.41 USD | -79.84% |
2015 Q3 | -0.01 USD | 99.95% |
2014 Q4 | -22.47 USD | -212081.13% |
2014 FY | - USD | -11384900.0% |
2014 Q3 | 0.01 USD | 10700.0% |
2014 Q2 | -0.00 USD | 0.0% |
2014 Q1 | -0.00 USD | 0.0% |
2013 Q4 | - USD | 100.0% |
2013 Q3 | -0.00 USD | 0.0% |
2013 Q2 | -0.00 USD | 0.0% |
2013 FY | - USD | 99.83% |
2013 Q1 | - USD | 100.0% |
2012 Q4 | -0.02 USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
GSRX Industries Inc. | - USD | NaN% |
High Sierra Technologies, Inc. | -0.02 USD | 100.0% |
Instadose Pharma Corp. | - USD | NaN% |